The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment.
暂无分享,去创建一个
Daniel J Sargent | Patrick J Heagerty | Holly Janes | Margaret S Pepe | Lisa M McShane | D. Sargent | P. Heagerty | M. Pepe | L. McShane | H. Janes
[1] D. Sargent,et al. Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.
[2] M. Bonetti,et al. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Tian,et al. Analysis of randomized comparative clinical trial data for personalized treatment selections. , 2011, Biostatistics.
[4] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[5] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[6] Margaret Sullivan Pepe,et al. Evaluating Markers for Selecting a Patient's Treatment , 2004, Biometrics.
[7] B. Freidlin,et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. , 2013, Journal of the National Cancer Institute.
[8] M. Bonetti,et al. Patterns of treatment effects in subsets of patients in clinical trials. , 2004, Biostatistics.
[9] P. Royston,et al. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials , 2004, Statistics in medicine.
[10] Donald B. Rubin,et al. Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .
[11] M. Dowsett,et al. International Web-based consultation on priorities for translational breast cancer research , 2007, Breast Cancer Research.
[12] Donglin Zeng,et al. Estimating Individualized Treatment Rules Using Outcome Weighted Learning , 2012, Journal of the American Statistical Association.
[13] Roland A Matsouaka,et al. Evaluating marker‐guided treatment selection strategies , 2014, Biometrics.
[14] Wenbin Lu,et al. Variable selection for optimal treatment decision , 2013, Statistical methods in medical research.
[15] D. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .
[16] P. Heagerty,et al. Analyzing longitudinal data to characterize the accuracy of markers used to select treatment , 2014, Statistics in medicine.
[17] Christine M. Micheel,et al. COMMITTEE ON THE REVIEW OF OMICS-BASED TESTS FOR PREDICTING PATIENT OUTCOMES IN CLINICAL TRIALS , 2012 .
[18] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[19] Willi Sauerbrei,et al. Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis , 2014, Statistics in medicine.
[20] R. Simon,et al. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.
[21] J. Dancey,et al. A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment , 2009, Journal of the National Cancer Institute.
[22] S. Murphy,et al. PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES. , 2011, Annals of statistics.
[23] Ji Zhu,et al. Variable Selection for Optimal Decision Making , 2007, AIME.
[24] Eric B. Laber,et al. A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.
[25] Holly Janes,et al. An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection , 2014, The international journal of biostatistics.
[26] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Richard Simon,et al. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. , 2008, European journal of cancer.
[28] Zhiwei Zhang,et al. The Use of Covariates and Random Effects in Evaluating Predictive Biomarkers Under a Potential Outcome Framework. , 2014, The annals of applied statistics.
[29] Holly Janes,et al. Measuring the Performance of Markers for Guiding Treatment Decisions , 2011, Annals of Internal Medicine.
[30] Holly Janes,et al. Assessing Treatment‐Selection Markers using a Potential Outcomes Framework , 2012, Biometrics.